Scott Rocklage Ph.D. has over thirty years of healthcare management experience. In 2004 he became a managing partner of 5AM Ventures. 5AM Ventures focuses on building the life science companies that are able to deliver impressive returns to their investors. They support companies who are working on health break throughs in regards to medicine and science. With strong scientific expertise; 5AM ventures are involved in setting company strategy as well as recruiting, developement and fundraising. Mr. Scott Rocklage‘s years of management experience within the health care industry helped him achieve FDA approval of three New Drug Applications within the United States. Those three drug applications are Omniscan™, Teslascan® and Cubicin®. Mr. Rocklage worked for Cubist Pharmaceuticals and Nycomed Salutar as a chairman and chief executive officer. Scott currently serves as a chairman of the board for Rennovia, Kinestral and Cidara as well as Epirus and Pulmatrix and more information click here.
Doctor Rocklage has an extensive educational background. He attended the University of California, Berkeley and earned his Bachelors in Chemistry. He then attended MIT and earned his Ph.D. in Chemistry. While attending MIT, Doctor Scott Rocklage was able to work on research in the laboratory of Richard R. Schrock. Richard R. was awarded the Nobel Prize in 2005 Chemistry and learn more about Scott.
Doctor Scott Rocklage is currently based out of Boston, Massachusettes. During his over thirty years in health care management he has been the inventor or co-inventor of over thirty united states patents. Dr. Rocklage has written over one hundred publications that are available for peer review and Scott’s lacrosse camp.
More visit: https://scottrocklage.wordpress.com/